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Nowadays, the major tasks of the increasing number of family cancer clinics are to provide general information about cancer, to
perform risk assessment, to oﬀer (presymptomatic) DNA-testing, to advise on lifestyle, to take steps for early detection and pre-
vention of cancer, for psychological support and to carry out research programmes by a multidisciplinary approach. In approxi-
mately 25–30% of the families with a hereditary pattern of breast cancer a germline mutation can be demonstrated, most commonly
in the BRCA1 and BRCA2 genes. Mutations in these genes are associated with high life-time risks of breast and ovarian cancer.
The introduction of MRI increased the sensitivity for early detection of breast cancer in comparison with mammography. Thusfar,
prophylactic bilateral total mastectomy is the most eﬀective and safest way of prevention but prophylactic oophorectomy and
chemoprevention are reasonable alternatives. In particular young women with children make use of DNA-testing and surgical
prevention. By a shared decision-making process, the patient and her medical doctor have to make the right choice of management
policy based on her individual circumstances.
# 2003 Elsevier Ltd. All rights reserved.1. Introduction
In the Western world, the incidence of breast cancer
has been doubled since 1940 [1]. There are approxi-
mately 1000 new cases per million women each year.
World-wide, a yearly incidence of nearly one million
new cases has been estimated. Breast cancer concerns
30% of all cancers in women and is the leading cause of
death in women between 35 and 55 years of age. In the
Western world, the life-time risk is 8–10%. In about
half of the women with primary breast cancer, occult
metastases (micrometastases) must be present at time of
diagnosis in view of the poor disease-free survival after
20 years of follow-up. The chance of metastases and
tumour progression is related with tumour stage,
tumour biological characteristics and patient age [2]. In
the long term, death occurred in 40% of patients withnode-negative disease, in 70% in node-positive disease,
and in nearly all women with clinically manifest meta-
static disease. However, since the improvements in
treatment, the large-scale application of adjuvant ther-
apy, the better information and awareness of women,
and probably the introduction of population-based
breast cancer screening programmes, the breast cancer
mortality rate is now decreasing in several countries.
Breast cancer is a multifactorial disease. An accumu-
lation of genetic alterations is responsible for the trans-
formation of normal cells into cancer cells. Several
hereditary (germline) and acquired (somatic) genetic
alterations are known to induce genomic instability,
resulting in a disbalance between cell proliferation and
cell death, and ultimately in tumour growth develop-
ment and progression [2].
15–30% of all women with breast cancer have at least
one relative with the disease, but it is currently esti-
mated that only 5–10% of cases are caused by inheri-
tance of germline mutations in highly penetrant
susceptibility genes such as BRCA1 and BRCA2 [3].1359-6349/03/$ - see front matter # 2003 Elsevier Ltd. All rights reserved.
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Mutations in the BRCA1 and BRCA2 genes have been
found in a quarter of families with familial breast cancer
[4]. Apart from germline mutations with a dominant
hereditary pattern of disease, an unknown number of
undiscovered susceptibility genes and modifying genes
conferring a lower risk may play an important role.
Possibly, as many as 15–27% of breast cancers may be
due to inheritable factors, which is higher than previous
estimates based on population studies [5]. Furthermore,
apart from hereditary predisposition, body character-
istics, endocrine and environmental factors (nutrition,
carcinogens, habits, radiation and viruses) are other
important causative factors of breast cancer [1]. In
addition, there is an interaction between hereditary,
reproductive and environmental factors.
In particular, the identiﬁcation of the breast cancer
susceptibility genes BRCA1 and BRCA2 in the mid-
1990s [6,7] evoked widespread interest in genetic and
oncological counselling and the need for multi-
disciplinary family cancer clinics. These clinics are
served by specialists of diﬀerent disciplines, which are
needed for an adequate support of all these women with
diﬀerent risks, problems and wishes. For instance, in
our family cancer clinic, at least 12 disciplines are
involved, as indicated in the Acknowledgements.2. Family cancer clinics
In the early 1990s, a number of these family cancer
clinics originated from research laboratories united in
the Breast Cancer Linkage Consortium (BCLC) [8–14].
The original main objectives of this consortium were to
detect predisposition genes for breast and ovarian can-
cer and to estimate risks of cancer related with these
genes. The localisation and identiﬁcation of the BRCA1
and BRCA2 genes are a nice example how the results of
laboratory research can be translated to the clinic and
routine care. In recent years, the number of family can-
cer clinics is rapidly increasing in line with the ever-
swelling numbers of families and individuals with a
proven gene mutation. There are also increasing colla-
borations at the national and international levels. Sev-eral collaborative groups and societies developed
guidelines and clinical research proposals [15–17].
Nowadays, the major tasks of family cancer clinics
are to provide general information about (breast) can-
cer, to perform risk assessment, to oﬀer (presympto-
matic) DNA testing, to advise on lifestyle, to take steps
for early detection and prevention of breast cancer, for
psychological support and to carry out research pro-
grammes (Table 1).
In Rotterdam, shortly after the localisation of
BRCA1 in 1990 [18], we established our Rotterdam
Family Cancer Clinic, which was in line with our early
studies on cell biological prognostic and predictive fac-
tors in breast cancers [2]. Since then, more than 1800
families with hereditary cancer have been registered
(Fig. 1) and more than 6000 people consulted our clinic.
The age at diagnosis of breast cancer in women with a
proven BRCA1/2 mutation was young in the majority
of the patients (Fig. 2) from the families who consulted
our family cancer clinic.3. Risk assessment
Risk assessment of breast cancer is originally based
on the family history and pedigree, and on other risk
factors [1]. Extensive genetic-epidemiological studies
in ﬁrst and second degrees of patients with breast
cancer resulted in valuable tables indicating the risk
estimates for family members of breast cancer
patients [19]. Familial occurrence of breast cancer can
increase the life-time risk of breast cancer up to
nearly 50%, depending on the number of breast can-
cer cases, young age of onset, presence of bilateral
disease and of other types of cancer such as ovarian
cancer. Well known familial breast cancer syndromes
are the hereditary breast cancer (HBC) only syndrome,
the hereditary breast/ovarian cancer (HBOC) syndrome
and Li–Fraumeni syndrome. These syndromes are
associated with clearly elevated risks of breast cancer.
Other risk factors such as endocrine and dietary factors
are associated with much lower relative risks (relative
risk <2) [1]. Also, histological characteristics of benign
proliferative breast disease are associated with an
increased risk (2–4 times) of breast cancer [1,20]. The
combination of atypical hyperplasia and familial
occurrence of breast cancer showed a strongly
enhanced risk (up to over 40% after 20 years of follow-
up) [19]. Breast cancer risk assessment can be per-
formed with the use of all these familial and non-
familial risk factors [21].
A more reﬁned and accurate assessment can be car-
ried out with the application of a presymptomatic DNA
test. Unaﬀected women with a proven BRCA1 or
BRCA2 mutation have a cumulative lifetime risk of
invasive breast cancer of approximately 55–85% and ofTable 1
The role of family cancer clinics1. General information on (breast) cancer2. Risk assessment3. DNA testing4. Advice on  lifestyle
 early detection
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4. Pathobiological characteristics and prognosisinvasive ovarian cancer of 15–65% [3,8–13,22]. Based on
population studies, unaﬀected BRCA1 or BRCA2 muta-
tion carriers without a clear family history seem to have
lower breast cancer risks (36–56%) but, at a family breast
cancer clinic, the familial occurrence of breast cancer is
mostly the reason for consultation. Compared with
BRCA1, the risk of breast cancer in BRCA2 mutation
carriers increased at a somewhat later age, thus showing a
lower penetrance at young age (less than 50 years) [13].
The BCLC also reported increased risk of other can-
cers than breast or ovarian cancer in large series of
families with BRCA1/2 mutations [8,12,13]. Signiﬁcantly
increased risks were found for prostate cancer, gastro-
intestinal tumours, pancreatic cancer, gallbladder and
bile duct cancer, and malignant melanoma, especially in
BRCA2 mutation carriers.BRCA1- and BRCA2-associated breast cancers show
diﬀerent histological and cell biological characteristics
in comparison to sporadic tumours [23–27]. BRCA1-
associated tumours show more frequently a high-grade
(poorly diﬀerentiated), medullary histological type, a
high proliferation index, more lymphocytic inﬁltration,
steroid receptor (ER-, PR)-negativity, low pS2 expres-
sion, presence of p53 mutations, HER2/neu-negativity,
topo-isomerase IIa-positivity, amplication of chromo-
some 6q 22-24 (the locus of c-myb), and possibly a low
expression of cyclin D1. With the exception of low
HER2/neu expression, nearly all factors are associated
with poor prognosis. Nevertheless, we found that the
prognosis of patients with BRCA1-associated tumoursFig. 1. Accrual Family Cancer Clinic Rotterdam (Dr Daniel den Hoed Kliniek/EMCR): number of families with family cancer syndromes.Fig. 2. Age at diagnosis of breast cancer in women with a BRCA1/BRCA2 mutation (n=346).J.G.M. Klijn, H. Meijers-Heijboer / EJC Supplements Vol 1 No. 1 (2003) 13–23 15
is similar or only somewhat less than those with spor-
adic tumours matched for patient age and year of diag-
nosis [28]. A few authors observed a signiﬁcant poor
prognosis for aﬀected BRCA1 mutation carriers [27,29].
With respect to BRCA2-associated tumours, these
tumours also show unfavourable tumour characteristics
but are less pronounced than for BRCA1-associated
tumours. However, there is no signiﬁcant diﬀerence
with respect to steroid hormone receptor-positivity in
comparison with sporadic tumours. When matched for
age and year of diagnosis, for aﬀected BRCA2 mutation
carriers also, we found no signiﬁcantly diﬀerent (dis-
ease-free) survival in comparison with breast cancer
patients in the general population [30,31].
In women with a BRCA1 or BRCA2 mutation, the
risk of a second primary (contralateral) breast carci-
noma is over 50% up to age 70 years. More speciﬁcally,
we showed that the 5-year rate of metachronous con-
tralateral breast carcinoma in women with a BRCA1 or
BRCA2 mutation was 19 and 12%, respectively, while
in age-matched controls this rate was 5 and 2%,
respectively [28,30,31]. Contralateral breast cancer risk
was greater in younger women (<50 years) with a
BRCA1-associated primary tumour than in older
women without aﬀecting overall survival [32].5. DNA testing
The identiﬁcation of the BRCA1 [6] and BRCA2 [7]
genes in 1994 and 1995 has had increasing clinical
impact. A large variety of mutations in both genes are
associated with inherited breast and/or ovarian cancer.
So mutation identiﬁcation is necessary in every family
with familial occurrence of breast and/or ovarian cancer.
In the context of a known mutation in the family, iden-
tiﬁcation of individuals with or without the mutation is
possible by (presymptomatic) DNA-testing [33–36].
Clearly, the absence or presence of a mutation will have
considerable medical and psychological signiﬁcance.
Results of several attitudinal studies have shown that
many (81–91%) of healthy ﬁrst-degree female relativesof patients with breast or ovarian cancer are potentially
interested in BRCA1/BRCA2 testing [37,38]. By con-
trast, actual use of the DNA test was signiﬁcantly lower
in women from families with an identiﬁed BRCA1
mutation [33,36]. In our clinical setting, we found in 682
unaﬀected individuals from 53 consecutive families with
an identiﬁed BRCA1/2 mutation that only 57% of
women and 22% of men with a genetic risk of 50% for
a mutation opted for a presymptomatic DNA test [36]
(Table 2). Important factors inﬂuencing a positive deci-
sion for BRCA1/BRCA2 testing were young age, par-
enthood, young age when for the ﬁrst time being
confronted with a breast cancer case in the family, and
the number of family members aﬀected with breast
cancer. Also, the wish for surgical prevention by pro-
phylactic mastectomy or oophorectomy was important.
BRCA1 and BRCA2 gene mutations are involved in
most families with the autosomal dominant inherited
breast–ovarian cancer syndrome, and in 60% of families
with 4 or more cases of just breast cancer before the age
of 60 years [10,13]. However, in the family cancer clinic
setting, the chance to ﬁnd a BRCA1/2 mutation (i.e.
detection rate) is much lower because smaller families
and families with less than 4 breast cancer cases are
more common. Both BRCA1 and BRCA2 genes are
large genes and germline mutations in these genes are
scattered throughout the coding sequences. Therefore,
both for reasons of practicality and cost-eﬀectiveness,
the probability that an individual with breast or ovarian
cancer may have a mutation in BRCA1/BRCA2 is an
important consideration in genetic testing. By using
various molecular genetic techniques [39–42] in 517
Dutch families at our Rotterdam family cancer clinic we
detected a BRCA1 (n=98; 19%) or BRCA2 (n=21;
4%) mutation in 119 (23%) families [4]. Predictors for
detection of a BRCA1/2 mutation are early-onset breast
cancer, one or more cases of ovarian cancer, and bilat-
eral disease. BRCA1/2 mutations were found in 52% of
138 families with HBOC, in 13% of 339 families with
HBC, in 36% of 11 families with ovarian cancer only
(HOC), and in none of 29 families with only one single
young case (<40 years) of breast cancer [4]. Between
the diﬀerent subgroups of families (subdivided by the
number of patients, cancer phenotype and age of onset),
the proportion of BRCA1/2 mutations detected varies
between 6 and 82%. Our results are in accordance with
those of others showing detection rates of approxi-
mately 20–30% in breast cancer risk evaluation clinics
[43–48].
The incidence of speciﬁc BRCA1/2 mutations varies
between populations. The ethnic background or regio-
nal origin can strongly inﬂuence the gene-mutation
detection rate. Diﬀerent founder mutations are found in
the Ashkenazi Jewish population and in Iceland, Nor-
way, Sweden, Poland, Austria, The Netherlands and
other countries [4,40–42,49–53]. In The Netherlands,Table 2
Predictive factors for utilization of DNA testing in 682 unaﬀected
subjects from 53 consecutive families with a BRCA1/2 mutation in
Rotterdam [36]Uptake P1. Pretest risk formutation (50 versus 25%) 58 versus 29% <0.0012. Gender (women versus men) 57 versus 22% <0.0013. Age in women (<50 versus550 years) 66 versus 38% <0.001
4. Parenthood (yes versus no) inwomen 65 versus 46% <0.004men 28 versus 9% <0.001N.B. Youngwomen (<50 years) with children 83% (90/108)N.B. Women with breast cancer 87% (68/78)16 J.G.M. Klijn, H. Meijers-Heijboer / EJC Supplements Vol 1 No. 1 (2003) 13–23
about 60% of all BRCA1/2 mutations detected concern
founder mutations some of them being speciﬁc for very
small conﬁned regions [4,40–42]. Apart from the migra-
tion characteristics of a population, religion and the
time period of origin of a speciﬁc mutation are impor-
tant factors with respect to geographical clustering of
founder mutations. Therefore, in addition to the famil-
ial cancer history (early onset breast cancer, bilateral
disease, ovarian cancer, clustering of other cancer
types), knowledge about the presence and prevalence of
founder mutations in speciﬁc populations is of impor-
tance for selecting families eligible for BRCA1/BRCA2
analysis and will greatly facilitate the detection of
mutations.6. Risk-reducing strategies
Current risk-reduction strategies aimed at prevention
of occurrence and/or death by cancer include changes in
lifestyle, early detection of cancer by regular surveil-
lance, prophylactic mastectomy, prophylactic oophor-
ectomy and chemoprevention [3,26,54–56].
6.1. Lifestyle
Women with a genetic predisposition for breast can-
cer can try to avoid other risk factors as far as possible
and to use optimal diets and to avoid alcoholic drinks.
These measures may decrease the risk or delay the
development of breast cancer, but major eﬀects can
probably not be reached. Age of menarche and age at
birth of ﬁrst child are physically and socio-
demographically determined and diﬃcult to inﬂuence.
In this respect, in The Netherlands the average age at
birth of ﬁrst child increased since 1970 from 24 to 30
years presently. Long-term use of contraceptive pills
from puberty reduce the risk of ovarian cancer with
about 50% [57], but may slightly increase the risk of
breast cancer [58], the tumour type which is more com-
mon at younger age. Thus, to give advice and to make
choices with respect to lifestyle is diﬃcult.
6.2. Early diagnosis by regular surveillance
Although an extensive international debate on the
value of population mammographic screening is ongo-
ing since the publication of Olson and Gotschke [59],
several randomised trials and population-based screen-
ing programmes indicate that mammographic screening
in the general population is eﬀective in postmenopausal
women and lowers breast cancer mortality by up to over
30% [1,60]. Although results in women between 40 and
50 years are more controversial, it was recently found
that screening in this age group can also signiﬁcantly
reduce breast cancer mortality [61]. However, in view ofthe lower incidence of breast cancer and the larger
negative screening eﬀects in young women [62], there is
no consensus on the cost-eﬀectiveness and the desir-
ability of introducing population-based screening pro-
grammes for women under the age of 50 years. It might
be more eﬃcient to limit screening in women under age
50 years to selected groups of high-risk women, such as
women with a positive family history of breast cancer.
The identiﬁcation of the BRCA1 and BRCA2 genes and
the possibility of gene mutation testing has caused an
increasing demand from high-risk women for genetic
testing and counselling about strategies to reduce their
risk of breast cancer death. One of the options is inten-
sive surveillance. Because, for ethical reasons, no ran-
domised trials in genetically susceptible women are to be
expected, the eﬀects of surveillance in these women must
be evaluated by means of observational studies. To date,
a limited number of studies describing experiences and
preliminary results of surveillance in women with a family
history of breast cancer have been published [63,64].
Nowadays, a number of countries, including The
Netherlands, oﬀer the opportunity of selective breast
cancer surveillance to women with a family history of
breast cancer. The current policy in 16 European
Family Cancer Clinics was recently reviewed by Vasen
and colleagues [65]. Current surveillance modalities are
breast self-examination, clinical examination and mam-
mography. Magnetic resonance imaging (MRI) is per-
formed mainly in research settings [66–70].
Most clinics recommend mammographic examination
every year instead of every 2 years, as the growth rate is
higher and the mammographic visibility of breast
tumours lower in younger women. There is no con-
sensus on the minimum age at entry: mammography
generally is performed for the ﬁrst time at age 25–35
years or 5–10 years younger than the youngest aﬀected
relative in case of young age at onset (<30–35 years).
Recently, we published the results of the ﬁrst studies
in BRCA1/2 gene mutation carriers in comparison with
women with high and moderate familial risk of breast
cancer [64]. In a study on 1198 women, the ratio of
observed number of cases versus breast cancers expected
in an average-risk population of comparable age was
23.7 in 128 BRCA1/2 gene mutations carriers, 7.0 in 621
high-risk women (30–50% lifetime risk), and 2.7 in 449
women with a moderate risk (15–30% lifetime risk).
Thus, the number of cancers detected was signiﬁcantly
greater than expected and related to the risk category.
Overall, the screening results were less favourable in the
youngest age group (<40 years) and in BRCA1/2 gene
mutation carriers.
In our second study, the yearly detection rate of breast
cancer in 139 BRCA1/2 mutation carriers by regular sur-
veillance was 2.5% after a median follow-up of 3 years
[68]. Nearly all tumours found were poorly diﬀerentiated
and ER-negative, and half of them node-positive.J.G.M. Klijn, H. Meijers-Heijboer / EJC Supplements Vol 1 No. 1 (2003) 13–23 17
It is uncertain whether mammographic surveillance of
premenopausal women with a BRCA1 or BRCA2
mutation contributes substantially to early detection of
breast cancer [64]. Considering the women’s young age
in our study cohort and the stage and pathological
characteristics of their breast cancers at diagnosis, we
estimate that 35–50% of women under surveillance in
whom primary breast cancer develops will die of distant
metastasis within 10–15 years [28,30]. Assuming that
within 10 years, breast cancer will develop in approxi-
mately 25% of the women undergoing regular surveil-
lance, we estimate that 10–20% of women who choose
surveillance will die of breast cancer within 20 years.
During the 3 years of follow-up in our study, there was
one death due to breast cancer [68].
Currently, several large, prospective studies are inves-
tigating whether MRI screening adds to the eﬃcacy of
mammographic screening in women at high risk for
breast cancer [66,67]. In our study on prophylactic
mastectomy versus surveillance, MRI was performed in
six women at the time of diagnosis and detected all six
cancers, but mammography was diagnostic in only two
of the eight women with breast cancer [68]. In view of
the high number of interval cancers (four of eight), the
use of high-resolution imaging and more frequent
screening might be useful in women with a BRCA1 or
BRCA2 mutation. Recent MRI studies showed that
MRI has a greater sensitivity (80–100%) than mammo-
graphy (33–45%) in this young age group [66–70], but
larger prospective studies with long-term follow-up are
needed. In this respect, several national MRI studies are
ongoing.
6.3. Prophylactic mastectomy
Early studies on the possible interest in prophylactic
mastectomy in untested high-risk women showed a wide
range of outcomes [34–38]. At our family cancer clinic,
51% of unaﬀected women with a proven mutation
choose prophylactic mastectomy, and 64% choose pro-
phylactic oophorectomy [36]. Predictive factors for pro-
phylactic mastectomy in unaﬀected BRCA1/2 mutation
carriers are young age and parenthood (Table 3). In
particular, young women with children opted for pro-phylactic mastectomy (70%) [36] as well as young
women with a longer awareness of the genetic nature of
cancer in the family [71]. No women older than age 55
years opted for prophylactic mastectomy, which is less
advisable in view of the signiﬁcantly declining estimated
gains in life expectancy with increasing age by this sur-
gical intervention [72]. In aﬀected mutation carriers with
primary breast cancer, 35% of the patients requested
prophylactic bilateral/contralateral mastectomy [73].
In our clinical practice, women increasingly base their
decision for prophylactic surgery on proven suscept-
ibility. Overall, since 1998, about 90% of high-risk
women based their choice for prophylactic mastectomy
on a proven BRCA1/BRCA2 mutation in contrast to
less than 20% before 1996 [36].
Until recently, only retrospective studies of the out-
come of prophylactic mastectomy (mainly sub-
cutaneous, and thus often incomplete) have been
published [26,54–56,74–76]. Hartmann and colleagues
[77] reported the results of prophylactic bilateral mas-
tectomy in 639 women with a family history of breast
cancer; at least 26 of these women had a BRCA1 or
BRCA2 mutation [78]. After a median follow-up of
14 years, there was an approximate 90% reduction in
the risk of breast cancer; the risk of death was also
reduced signiﬁcantly. All seven breast cancers occur-
red after subcutaneous bilateral mastectomy; there
was none after total mastectomy [77]. Moreover,
breast cancer did not develop in any of the women
with a conﬁrmed BRCA1 or BRCA2 mutation after a
median follow-up of 13 years (range 6–28 years) [78],
which leads us to anticipate that prophylactic mas-
tectomy will reduce the long-term risk of breast can-
cer in the women with a BRCA1 or BRCA2
mutation whom we studied.
After a number of retrospective studies in high-risk
women without a proven BRCA1/2 mutation showing a
risk-reduction of approximately 90%, we performed the
ﬁrst (prospective comparative cohort) study in 76
BRCA 1/2 mutation carriers [68]. No cases of breast
cancer were observed after prophylactic mastectomy
after a mean (SE) follow-up of 2.91.4 years,
whereas eight breast cancers developed in women under
regular surveillance after a mean follow-up of 3.01.5
years (P=0.003; hazard ratio, 0; 95% Conﬁdence
Interval (CI) 0–0.36). The actuarial mean 5-year inci-
dence of breast cancer among all women in the surveil-
lance group was 177%. On the basis of an
exponential model, the yearly incidence of breast cancer
in this group was 2.5%.
There is little in the literature on the histological
ﬁndings in specimens obtained at the time of prophy-
lactic mastectomy from women with a BRCA1 or
BRCA2 mutation. In two studies, in about 35% of
unaﬀected high-risk women, proliferative breast disease
(marked or atypical hyperplasia) was found in theTable 3
Predictive factors for prophylactic mastectomy in unaﬀected BRCA1/2
mutation carriers1 Overall use in eligible women 35/68 (51%)2 Age <40 years 21/38 (55%)40–54 years 13/21 (62%)555 years 1/9 (11%) P=0.06
3 Parenthood No children 2/14 (14%)With children 33/54 (61%) P=0.0062+3 Women <50 years with children 28/40 (70%)Source: Ref. [36].18 J.G.M. Klijn, H. Meijers-Heijboer / EJC Supplements Vol 1 No. 1 (2003) 13–23
surgical specimens [79,80]. In contrast, this abnormality
was found in specimens from only 13% of women with
an average risk of breast cancer [80]. In two women with
a strong family history of breast cancer, microcalciﬁca-
tions and invasive breast cancer were detected within 1
year after the ﬁnding of proliferative disease [80]. In
contralateral specimens obtained at the time of prophy-
lactic mastectomy from women with prior breast cancer
and either a genetic risk or a family history of breast
cancer, a higher prevalence of malignant lesions was
observed [54,79]. In our study [68], there was one carci-
noma in situ and several prophylactic-mastectomy spe-
cimens with various degrees of hyperplasia and atypia.
However, we cannot exclude the possibility that small
invasive tumours were overlooked.
The utilisation of both prophylactic surgery and
DNA testing in our centre may diﬀer from those in
other countries for several reasons. In The Netherlands,
cancer susceptibility is no ground for exclusion by the
health insurance system, or in access to employment.
Costs for genetic testing, surveillance and prophylactic
surgery are covered by both public and private health
insurances. Accordingly, families and risk carriers are free
from social or ﬁnancial constraints, something that may
be diﬀerent in other countries. The risk for social and
ﬁnancial discrimination has been noted as an important
reason to refrain from BRCA1/2 testing [77,81]. Further-
more, cultural diﬀerences in views on health and disease,
risks and prevention, paternalism versus autonomy, and
femininity may greatly inﬂuence interests in presympto-
matic DNA testing and prophylactic surgery [54,82].
In a very recent study from Manchester, United
Kingdom [83], the utilisation of prophylactic mas-
tectomy appeared to be increased to 61% in BRCA1/2
carriers which results are in agreement with our pub-
lished data [36,68]. Also in the United States of America
there is an increasing demand for prophylactic surgery
[75,76]. Unpublished results of a study by Lynch and
colleagues [76] showed that 38% of woman considered
prophylactic mastectomy before DNA testing: after
learning of their BRCA1 or BRCA2 mutation status,
172 (51%) of the 336 mutation-positive women opted
for bilateral prophylactic oophorectomy. A follow-up
survey found that 27 (19%) of 142 mutation-positivewomen had actually undergone bilateral prophylactic
mastectomy, while 46 (35%) of 131 mutation-positive
women had had a bilateral prophylactic oophorectomy.
Prophylactic mastectomy is a highly personal deci-
sion. In counselling high-risk women, the protective
eﬀect of prophylactic mastectomy must be weighed
against possible surgical complications and psychologi-
cal problems. Up to 30% of the women who undergo
the procedure will have surgical complications, depend-
ing on the type of surgery and the length of follow-up
[74,75,84]. A long-term study of prophylactic mas-
tectomy reported unanticipated repeated operations in
49% of women [85], but these results may not be
applicable to prophylactic mastectomies as they are
currently performed as also in our experience [86]. Psy-
chological studies of women who had undergone a pro-
phylactic mastectomy did not ﬁnd that, overall, the
procedure had detrimental eﬀects on body image and
sexuality [87–90].
In conclusion, our data [68] and those of Hartmann
and colleagues [77,78] indicate that prophylactic bilat-
eral total mastectomy substantially reduces the inci-
dence of breast cancer among women with a BRCA1 or
BRCA2 mutation. Nevertheless, longer follow-up and
studies of more patients are required to establish the
protective eﬀect and determine the long-term compli-
cations of this procedure.
6.4. Endocrine prevention
Endocrine prevention of breast cancer can be per-
formed by ovarian ablation or by treatment with anti-
oestrogens [3,26,54–56,91]. Prophylactic bilateral
oophorectomy reduces not only the risk of ovarian
cancer with about 95% in BRCA1/2 gene mutation
carriers or in women from families with a HBOC syn-
drome [92], but also reduces the risk of breast cancer by
approximately 50%. Rebbeck and colleagues [93]
demonstrated in 43 intact BRCA1 mutation carriers a
risk reduction of breast cancer by 47% in comparison
with 79 controls (Table 4), a reduction which was
recently conﬁrmed in a larger series of women [94]. In
line with these ﬁndings were the results of a study in
aﬀected BRCA1/2 mutation carriers with primaryTable 4
Risk reduction of (contralaterala) breast cancer by prophylactic oophorectomy or chemoprevention in hereditary breast cancerAuthor Measure Group Cases Controls HR (95% CI)Rebbeck [93] Oophorectomy BRCA1+ 43 79 0.53 (0.33–0.84)Naroda [95] Oophorectomy BRCA1/2+ 13 57 0.42 (0.22–0.83)Powles [98] Tamoxifen Familial BC51 1230 1230 No diﬀerence
Fisher [96] Tamoxifen Familial BC51 5036 5004 0.51–0.55
King [99] Tamoxifen BRCA1+ 5 3 1.67 (0.32–10.7)Tamoxifen BRCA2+ 3 8 0.38 (0.06–1.56)Naroda [95] Tamoxifen BRCA1/2+ 22 81 0.50 (0.28–0.89)Naroda [95] Chemotherapy BRCA1/2+ 88 234 0.40 (0.26–0.60)J.G.M. Klijn, H. Meijers-Heijboer / EJC Supplements Vol 1 No. 1 (2003) 13–23 19
breast cancer showing that prophylactic oophorectomy
reduced the incidence of contralateral breast cancer by
58% [95].
Results of several trials on the eﬃcacy of pharmaco-
logical intervention (chemoprevention) with anti-oes-
trogens such as the selective oestrogen receptor
modulators (SERMS) tamoxifen and raloxifen have
been published [26,91]. Both the NSABP P-1 trial on
13 388 women (49% reduction with tamoxifen) [96] and
the MORE trial on 7705 postmenopausal women with
existing osteoporosis (>70% reduction with raloxifene)
[91] showed a signiﬁcant decrease of the incidence of
breast cancer by long-term use of anti-oestrogens.
However, two randomised European trials from the UK
and Italy showed no signiﬁcant reduction of the risk of
breast cancer by tamoxifen [26,54–56,91]. The results of
a ﬁfth chemoprevention study (IBIS 1) testing tamox-
ifen versus placebo [56] have been presented at the 3rd
European Breast Cancer Conference in Barcelona
(March 2002) and were recently published [97]. In these
studies not all women had an increased risk by a famil-
ial history of breast cancer or a proven BRCA1/2 gene
mutation. Nevertheless, in the NSABP P1 trial [96] over
10 000 women had a family history of breast cancer and
in these large subgroups the risk reduction (45–49%)
was similar to that in the total study population. In
contrast, in the study of Powles and co-workers [98] on
about 2500 women with a family history of breast can-
cer, no risk reduction by tamoxifen was observed. With
respect to proven BRCA1/2 mutation carriers, King
found a BRCA1 or BRCA2 mutation in 19 out of 310
participants who developed breast cancer within the P1
chemoprevention trial [99]. From the 11 patients with a
BRCA2 mutation 8 were in the placebo group and 3 in
the tamoxifen group (risk ratio 0.38; 95% CI 0.06–1.56).
In contrast, from the 8 patients with a BRCA1 muta-
tion, only 3 were in the placebo group and 5 in the
tamoxifen treatment arm (risk ratio 1.67; 95% CI 0.32–
10.7). Such risk ratios might be expected because
BRCA2-associated tumours are mostly ER-positive andBRCA1-associated tumours mainly ER-negative
[31,99]. However, the numbers are much too small to
draw deﬁnitive conclusions, as indicated by the wide 95%
CIs and consequently the lack of statistical signiﬁcance.
However, in aﬀected BRCA1/2 mutation carriers with a
primary tumour, Narod and colleagues showed a 50%
reduction of contralateral breast cancer by adjuvant
tamoxifen; in addition, adjuvant chemotherapy caused a
60% reduction of contralateral breast cancer [95].7. In conclusion
Together with the identiﬁcation of important predis-
position genes for breast cancer and better deﬁned
associated risks, there is an increasing demand for (pre-
symptomatic) DNA testing. Thus far, prophylactic
bilateral total mastectomy is the most eﬀective and
safest way of prevention of breast cancer but, for
women above the age of 40 years, prophylactic
oophorectomy is a reasonable alternative. With respect
to chemoprevention, we are in favour of the use of this
option mainly within the context of clinical trials. The
introduction of MRI will increase the sensitivity for
early detection of breast cancer in comparison with
mammography, but prevention of death by breast can-
cer cannot guaranteed. Finally, by a shared decision-
making process, the patient and her medical doctor
have to make the right choice of management policy
based on her individual circumstances.Acknowledgements
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